Quick Takeaways
- Voss Capital, LP filed SCHEDULE 13G/A for Rein Therapeutics, Inc. Common Stock, $0.001 par value (RNTX).
- Disclosed ownership: 11%.
- Date of event: 24 Sep 2025.
Quoteable Key Fact
"Voss Capital, LP disclosed 11% ownership in Rein Therapeutics, Inc. Common Stock, $0.001 par value (RNTX) on 24 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Voss Value Master Fund, LP | 3% | 699,440 | 699,440 | 0 | /s/ Travis W. Cocke | Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner | |
| Voss Value-Oriented Special Situations Fund, LP | 1.3% | 316,768 | 316,768 | 0 | /s/ Travis W. Cocke | Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner | |
| Voss Advisors GP, LLC | 4.3% | 1,016,208 | 1,016,208 | 0 | /s/ Travis W. Cocke | Travis W. Cocke, Managing Member | |
| Voss Capital, LP | 11% | 2,666,532 | 2,666,532 | 0 | /s/ Travis W. Cocke | Travis W. Cocke, Managing Member | |
| Cocke Travis W. | 11% | 2,666,532 | 2,666,532 | 0 | /s/ Travis W. Cocke | Travis W. Cocke |